The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus
- 1 May 2009
- journal article
- review article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 20 (3), 253-260
- https://doi.org/10.1016/j.ejim.2008.07.008
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetesAmerican Heart Journal, 2007
- Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptorProceedings of the National Academy of Sciences, 2006
- Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 DiabetesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Combined Effects of Hemoglobin A 1c and C-Reactive Protein on the Progression of Subclinical Carotid AtherosclerosisStroke, 2006
- C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and WomenCirculation, 2005
- Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) studyAmerican Heart Journal, 2005
- More Fibrosis and Thrombotic Complications but Similar Expression Patterns of Markers for Coagulation and Inflammation in Symptomatic Plaques from DM2 PatientsJournal of Histochemistry & Cytochemistry, 2004
- Low‐grade inflammation, endothelial activation and carotid intima‐media thickness in type 2 diabetesJournal of Internal Medicine, 2004
- Joint Effects of C-Reactive Protein and Glycated Hemoglobin in Predicting Future Cardiovascular Events of Patients With Advanced AtherosclerosisCirculation, 2003
- Atorvastatin Lowers C-Reactive Protein and Improves Endothelium-Dependent Vasodilation in Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2002